Cetuximab in metastatic colorectal cancer

The Lancet Oncology

Volumn 11, Issue 4, 2010, Pages 313-314

  Wolf, Ido ^a   Golan, Talia ^a   Shani, Adi ^a   Aderka, Dan ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; K RAS PROTEIN;

CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; LETTER; LIVER METASTASIS; LIVER RESECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; ENDPOINT DETERMINATION; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RESEARCH DESIGN;

EID: 77950311726     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70019-X     Document Type: Letter

References (2)

1. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47.
2. Folprecht G, Gruenberger T, Hartmann JT, et al. Randomized multicenter study of cetuximab plus FOLFOX or plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (celim-study). Ann Oncol 2008, 19:168.